Nevertheless, the mechanism of GIP-stimulated adipocyte lipolysis, rather than triglyceride storage, could potentially be an anti-obesity mechanism for pharmacological doses of GIPR agonists to overcome the anti-lipolytic effects of insulin. The gene discussed is GIPR; the disease is obesity due to melanocortin 4 receptor deficiency.